SQZ News and Press, SQZ Biotechnologies Company From 11/09/22

SQZ Biotechnologies press release ( NYSE: SQZ ): Q3 GAAP EPS of -$0.77 beats by $0.06 . Revenue of $3.5M (-27.1% Y/Y) misses by $0.76M . Company had cash and cash equivalents of $84.2 million and anticipates this will be sufficient to fund operating expenses an...

Published Comprehensive Preclinical Research on SQZ ® AAC Platform in Frontiers in Immunology Continued Investigational New Drug-Enabling Activities for SQZ ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manuf...

SQZ Biotechnologies ( NYSE: SQZ ), a biotech focused on cell therapies, added ~5% pre-market Thursday after H.C. Wainwright launched its coverage with a Buy rating and a $5 target highlighting the company’s Cell Squeeze technology platform. The analyst Emily Bod...

Activating Antigen Carriers (AACs) Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor Killing Demonstrated Improved Efficacy of AAC Therapy Through Combination with Chemotherapy Agent SQZ Biotechnologies Company (NYSE: ...

TILs Engineered to Temporarily Express Membrane-Bound IL-2 and IL-12 Could Potentially Improve TIL Function While Simultaneously Eliminating the Need for Toxic Preconditioning and Cytokine Administration Data Presented at ESMO 2022 Show SQZ ® TILs Enhanced Pro...

Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company’s Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chem...

On May 18, I wrote the first of three articles stating that healthcare stocks, and specifically biopharmaceuticals, had likely bottomed. XBI was at 68 and IBB 114. Both XBI and IBB have increased since then. I viewed the valuations a few months ago as being compelling in several insta...

SQZ Biotechnologies press release ( NYSE: SQZ ): Q2 GAAP EPS of -$0.78 misses by $0.01 . Revenue of $3.22M (-29.1% Y/Y) misses by $0.97M . “We are excited by meaningful progress in our clinical trials and also the receipt of FDA Fast Track Designation ...

Granted FDA Fast Track Designation for APC Clinical Candidate Published Comprehensive Preclinical Research on SQZ ® TAC Platform in Frontiers in Immunology Presented First SQZ ® Point-of-Care (POC) Manufacturing System Performance Data; Initial ...

ESMO Immuno-Oncology and Technology Article Details Importance of Intracellular Delivery to Drive Effective MHC-I Mediated Activation of CD8 T Cells Paper Highlights Preclinical SQZ ® APC Combination Data with PD-1 IL2v and Manufacturing Benefits of the Cell S...